What is Okomera?
Okomera is at the forefront of revolutionizing drug discovery by integrating critical assays, such as CRISPR, T-cell, and cytotoxicity testing, directly onto a chip. This technological advancement aims to significantly accelerate the journey from target identification to validation, enhancing the predictive accuracy of preclinical studies. The company's platform is designed to streamline the complex process of therapeutic development, offering a more efficient and reliable pathway for pharmaceutical and biotechnology firms.
How much funding has Okomera raised?
Okomera has raised a total of $1.6M across 1 funding round:
Grant
$1.6M
Grant (2024): $1.6M with participation from Institut Paoli-Calmettes
Key Investors in Okomera
Institut Paoli-Calmettes
Institut Paoli-Calmettes, a prominent cancer care and research center, has provided backing to Okomera. Their involvement suggests a strategic interest in novel drug discovery technologies that can accelerate cancer research and treatment validation.
What's next for Okomera?
With the infusion of $1.6M in a major strategic investment, Okomera is poised for significant expansion and further technological refinement. This capital injection, part of its $1.6M in total funding, will likely fuel advancements in its assay integration capabilities and broaden its market reach. The company's focus on enhancing preclinical predictivity positions it as a key player in the evolving landscape of drug development, potentially attracting further strategic partnerships and investments as it moves towards commercialization and broader adoption of its platform.
See full Okomera company page
